FDG-PET correctly differentiated benign from malignant adrenal lesions, with a significantly higher mean tumor-to-background ratio for malignant (7.4) versus benign (0.8) lesions (P<.001).
Observational (n=20)
Does FDG-PET accurately differentiate benign from malignant adrenal masses in patients with cancer?
FDG-PET accurately differentiates benign from malignant adrenal masses in patients with cancer, demonstrating significantly higher tumor-to-background ratios in malignant lesions.
Tasa de eventos absoluta: 7.4% vs 0.8%
valor p: p=< .001
PURPOSE: To evaluate the ability of positron emission tomography (PET) to characterize adrenal masses in patients with cancer. MATERIALS AND METHODS: Twenty-four adrenal masses (size range, 1.5-10.0 cm mean, 2.8 cm) in 20 patients (13 men and seven women) with cancer (lung n = 10, colon n = 3, lymphoma n = 3, miscellaneous n = 4) were evaluated. PET was performed in fasting patients 45 minutes after infusion of 5-10 mCi (185-370 MBq) of 2-fluorine-18-fluoro-2-deoxy-D-glucose (FDG). PET images were correlated with findings at computed tomography (CT), surgery, and/or percutaneous biopsy. RESULTS: Fourteen adrenal masses were proved malignant at surgery (n = 4), biopsy (n = 7), or follow-up (n = 3). Ten lesions were proved benign at biopsy (n = 4) or follow-up CT (n = 6). PET helped correct differentiation of benign from malignant adrenal lesions in all patients. A statistically significant difference (P < .001) was seen between mean tumor-to-background ratios for malignant (mean, 7.4; range, 2.9-16.6; median, 6.9) versus benign (mean, 0.8; range, 0.2-1.2; median, 0.6) adrenal lesions. CONCLUSION: PET helped correct differentiation of benign from malignant adrenal lesions.
Boland et al. (Sun,) conducted a observational in Cancer with indeterminate adrenal mass (n=20). FDG-PET vs. Benign lesions (reference standard: CT, surgery, biopsy) was evaluated on Tumor-to-background ratio (p=< .001). FDG-PET correctly differentiated benign from malignant adrenal lesions, with a significantly higher mean tumor-to-background ratio for malignant (7.4) versus benign (0.8) lesions (P<.001).